UK Parliament / Open data

Health Service Medical Supplies (Costs) Bill

The noble Lord referred to me-too drugs. I hope that he agrees that it is important to recognise that such drugs have often been developed in parallel. They do not take a molecule and just copy it; they develop a new molecule or delivery system, often to minimise side-effects and to maximise efficacy. But they also have a production cost behind them. They are not just copies of something previously produced and marketed differently; they have innovation behind them as well.

About this proceeding contribution

Reference

778 c42GC 

Session

2016-17

Chamber / Committee

House of Lords Grand Committee
Back to top